Finance

Lists
Q2 2027 earnings • released • EPS beat +16.48% • Revenue beat +4.13%
See results
MANKIND:NSE
Mankind Pharma Ltd
₹2,492.80
+0.95%
(+23.50) 1D
Oct 30, 3:30:00 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for MANKIND...
Open
₹2,469.30
High
₹2,528.00
Low
₹2,467.40
Mkt. cap
1.03T
Avg. vol.
742.10K
Volume
681.50K
P/E ratio
45.93
52-wk high
₹2,642.00
52-wk low
₹1,909.70
EPS
₹54.27
No. of employees
20K
Open
₹2,469.30
High
₹2,528.00
Low
₹2,467.40
Mkt. cap
1.03T
Avg. vol.
742.10K
Volume
681.50K
P/E ratio
45.93
52-wk high
₹2,642.00
52-wk low
₹1,909.70
EPS
₹54.27
No. of employees
20K
News stories
From web sources and news partners
Profile
Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in Delhi. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications. As of 2023, Mankind Pharma had 25 factories and 6 R&D centres in India. The company derived 97% of its operating revenue from the Indian market, where it is reportedly the fourth largest pharmaceutical company by domestic sales. Some of Mankind Pharma's consumer healthcare brands are the largest-selling in their respective categories, including Manforce in condoms, Prega News in pregnancy test kits, and Unwanted-72 in emergency contraception. Wikipedia
About Mankind Pharma Ltd
CEORajeev Juneja | Sheetal Arora
Employees20.5K
Founded1991
Headquarters-
SectorPharmaceutical industry
Websitemankindpharma.com
Last report
Oct 26, 2026
Fiscal period
Q2 2027
₹17.20 / ₹14.77
+16.48%beat
Revenue / Est. (INR)
43.38B / 41.66B
+4.13%beat
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
35.67B
34.43B
40.31B
43.38B
Cost of goods sold
9.78B
11.71B
10.98B
12.04B
Cost of revenue
9.78B
11.71B
10.98B
12.04B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.24B
15.80B
9.14B
9.49B
Operating expense
18.92B
14.77B
21.02B
21.98B
Total operating expenses
28.70B
26.48B
32.00B
34.02B
Operating income
6.97B
7.95B
8.30B
9.36B
Other non operating income
727.50M
-2.31B
450.00M
948.50M
EBT including unusual items
5.09B
6.59B
7.69B
9.29B
EBT excluding unusual items
6.16B
5.59B
7.69B
9.29B
Income tax expense
951.20M
997.50M
1.95B
2.13B
Effective tax rate
18.69%
15.13%
25.39%
22.92%
Other operating expenses
8.46B
-3.26B
9.63B
10.13B
Net income
4.09B
5.54B
5.68B
7.11B
Net profit margin
11.46%
16.10%
14.09%
16.40%
Earnings per share
11.99
13.89
13.74
17.20
Interest and investment income
-
580.50M
-
-
Interest expense
-1.57B
-1.36B
-1.10B
-1.05B
Net interest expenses
-1.57B
-778.20M
-1.10B
-1.05B
Depreciation and amortization charges
2.23B
2.23B
2.26B
2.36B
EBITDA
8.42B
9.97B
10.33B
11.66B
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps